1.
|
Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Active Age: 20 and over Sponsor: Other Protocol IDs: 9461700718, NCT00173524
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913C00046, NCT00536107
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913L00071, NCT00770588
|
|
4.
|
Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0555, D7913L00008, NCT00357734
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ONC-2008-001, NCT00807066
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CHNMC-03049, IRB 03049, ZENECA-1839US/0274, ZENECA-IRUSIRES0012, NCT00086957
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NP01/07/03, NCT00212108
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: NS 01/03/08, NCT00809237
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ID02-282, NCT00054691
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MCC-13922, ZENECA-IRUSIRES0256, MCC-IRB-102794, NCT00104728
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SWS-SAKK-70/03, EU-20526, NCT00238251
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CASE-CCF-5538, ZENECA-1839IL/0234, NCT00268346
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0562, NCT00228501
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GORTEC 2004-02, NCT00169221
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: JHOC-J0386, J0386, JHOC-04-02-20-03, ZENECA-IRUSIRES0304, NCT00493025
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 13503A, NCT00519077
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: YONSEI-4-2006-0136, 4-2006-0136, ZENECA-YONSEI-4-2006-0136, NCT00616499
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 04-071, CA113653, NCT00588445
|
|
19.
|
Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: POCPZD, IRUSIRES0181, NCT00132158
|
|
20.
|
Phase: Phase I Type: Supportive care, Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: ZD1839, NCT00186979
|
|
21.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 03C.225, NCT00328562
|
|
22.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FDCA001, NCT00497250
|
|
23.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NS01/19/05, NCT00717847
|